Literature DB >> 21404553

[Prognosis of surgically treated large cell neuroendocrine carcinoma].

Natsumi Matsuura1, Nariyasu Nakashima, Hitoshi Igai, Shintarou Tarumi, Sung-Soo Chang, Noriyuki Misaki, Dage Liu, Tetsuhiko Go, Shinya Ishikawa, Cheng-Long Huang, Hiroyasu Yokomise.   

Abstract

Large cell neuroendocrine carcinoma (LCNEC) is a relatively rare tumor in malignant lung neoplasms. The prognosis of LCNEC is poor and there is no consensus on the treatment for LCNEC. We report our retrospective assessment of 11 patients of LCNEC from 1999 to 2008. Three of 11 patients had malignant exudate at thoracotomy. Seven patients received limited resection. There was a recurrence even after complete surgical resection in its early stage. Four patients received platinum-based chemotherapy for adjuvant therapy or recurrence. The response to platinum-based chemotherapy was relatively good and may be comparable to that of small cell lung cancer. The overall 5-year survival rate was 30.3%. Pulmonary LCNEC represents an aggressive tumor and multimodal treatment is required.

Entities:  

Mesh:

Year:  2011        PMID: 21404553

Source DB:  PubMed          Journal:  Kyobu Geka        ISSN: 0021-5252


  2 in total

1.  The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung.

Authors:  Jianjun Gu; Daohui Gong; Yuxiu Wang; Beiyuan Chi; Jun Zhang; Suwei Hu; Lingfeng Min
Journal:  Cancer Med       Date:  2019-05-14       Impact factor: 4.452

2.  Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage.

Authors:  Anna Lowczak; Agnieszka Kolasinska-Cwikla; Karolina Osowiecka; Lidia Glinka; Jakub Palucki; Robert Rzepko; Anna Doboszynska; Jaroslaw B Cwikla
Journal:  Medicina (Kaunas)       Date:  2021-01-28       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.